摘要
目的探讨超声作用下微泡携肝细胞生长因子（HGF）对大鼠肝纤维化的治疗效果。方法构建真核表达质粒pMD18-T／HGF；将实验大鼠随机分为5组：正常组、模型组、低剂量组、中剂量组、高剂量组。建立肝纤维化模型，治疗14d后处死大鼠，取血行检测丙氨酸转氨酶（ALT）评价肝功能，病理切片HE染色评价纤维化程度，免疫组化SABC法观察HGF蛋白，RT-PCR检测HGFmRNA。结果治疗组治疗后血清肝功能优于模型组（P〈0．05），低剂量组与正常组间差异有统计学意义（P〈0．05），中、高剂量组与正常组间差异无统计学意义（P〉0．05）。病理切片示治疗组纤维化减轻；免疫组化见各治疗组HGF阳性表达，表达量随治疗剂量增高而增大（P〈0．05）。RT-PCR示各治疗组HGFmRNA表达高于模型组，且随治疗剂量的增大而增高（P〈0．05）。结论超声作用下微泡携HGF可以有效抑制肝纤维化进程，其治疗效果在一定范围内随着治疗剂量的增大而增强。
Objective To investigate the efficiency of ultrasound microbubble-mediated t-ltgY gene transfer on liver fibrosis in rats. Methods The eukaryotic expression vector pMD18-T/HGF was constructed. The rats were randomly divided into 5 groups., normal group, model group, low dose group, middle dose group and high dose group. The rat liver fibrosis were induced. At day 14 after treatment, the rats were sacrificed, the ALT lever were evaluated, pathological evaluation of liver fibrosis were made, immunohistochemical evaluation of HGF protein expressions were observed, HGF mRNA expression were detected by RT-PCR. Results Liver 1function after the treatment showed that the treatment groups were better than model group （ P〈0.05）. The difference between low dose group and normal group showed significant difference （P 〈0.05）, and the difference between middle/high dose groups and normal group showed no significant （ P 〈0.05）. Pathological results showed that the treatment groups could reduce liver fibrosis treatment groups had the positive HGF expression by immunohistochemistry and the expression level increased with the increasement of the treatment dose （ P 〈0.05）. RT-PCR showed HGF mRNA expression in the treatment groups were higher than in model group （ P 〈0.05）. Conclusions Ultrasound microbubbles which carrying HGF can inhibit the process of hepatic fibrosis.
出处
《中华超声影像学杂志》
CSCD
北大核心
2011年第8期707-710,共4页
Chinese Journal of Ultrasonography
基金
浙江省科技计划项目（2008C33057）
关键词
超声检查
微气泡
肝硬化
肝细胞生长因子
Ultrasonography
Microbubbles
Liver cirrhosis
Hepatocyte growth factor
